Ripretinib predominantly induces ADRs reflecting significant tumor volume changes and vascular alterations, such as hepatic embolization, which might be attributed to the profound vascular disruption caused by VEGFR pathway inhibition (Roskoski, 2021). This evidence concerns the gene KDR and neoplasm.